We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 27 Jul 2015
Print article
Image: The AtomoRapid lateral flow immunoassay diagnostic platform (Photo courtesy of Atomo Diagnostics).
Image: The AtomoRapid lateral flow immunoassay diagnostic platform (Photo courtesy of Atomo Diagnostics).
A novel rapid point-of-care assay for the diagnosis of Ebolavirus infection was introduced at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).

BBI Solutions (Cardiff, United Kingdom), a biotech company that supplies a range of mouse monoclonal antibodies for detecting the Ebola virus, announced from its booth (3665) at the AACC Annual meeting that that it would soon release a rapid test for Ebola in association with the technology transfer company Ploughshare Innovations (Stockbridge, United Kingdom).

The test is built around the highly regarded Atomo Diagnostics (Sydney, Australia) lateral flow technology and provides a result in approximately 20 minutes. Five Ebola antibodies against the Zaire and Sudan strains of Ebolavirus have been tested successfully with this system. BBI Solutions also provides a panel comprising 13 different monoclonal antibodies, to the Zaire and Sudan strains.

The lateral flow test has already been evaluated in the field. In trials in Sierra Leone a 100% detection rate was achieved for 138 participants. At low positive levels the test achieved 100% sensitivity and 92% specificity, and at a high positive, 100% sensitivity and 97% specificity. This performance suggests that the BBI Solutions assay is potentially more sensitive and specific than other lateral flow or dipstick type assays currently available.

Leigh Thomas, chief commercial officer at BBI Solutions, said, “BBI has developed high performance lateral flow tests for some of the world’s leading diagnostic companies for over 25 years. Our expertise and flexibility has allowed us to quickly deploy a team and develop a rapid test in nine months which, based on field testing, promises to have an immediate and positive impact on the Ebola crisis. We are pleased that our test will meet an immediate need in the field and ultimately improve the lives of others.”

Related Links:
2015 AACC Annual Meeting & Clinical Lab Expo
BBI Solutions
Atomo Diagnostics


Gold Member
Troponin T QC
Troponin T Quality Control
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Parasite Suspension for QC
Cryptosporidium Species Parasite Suspension
New
RNA Isolation Kits
RNeasy Plus Kits for RNA Isolation

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.